Literature DB >> 32288919

Load reduction in live PRRS vaccines using oil and polymer adjuvants.

Sebastien Deville1, Juliette Ben Arous1, Ghislaine Ionkoff1, François Bertranda Sergey Kukushkin2, Taufik Baybikov2, Vladimir Borisov2, Laurent Dupuis1.   

Abstract

PRRSV live vaccines are widely used in pig farming practice and are usually not adjuvanted. For safety issues, it would be useful to reduce the antigenic load of such vaccines while preserving their efficacy. In this study we show that the addition of polymer or oil adjuvants in a PRRS live vaccine enhanced the protection to challenge of vaccinated animals compared to a non-adjuvanted commercial reference. Moreover, for both types of adjuvants, despite lower antibody titers, the protection to challenge given by the adjuvanted vaccine containing only 50% of the antigen load was equivalent to the protection given by the non-adjuvanted vaccine. These results demonstrate that the addition of relevant adjuvants can enhance the efficacy of the protection conferred to animals by live vaccines.
Copyright © 2012 Published by Elsevier B.V.

Entities:  

Keywords:  Montanide; PRRS; adjuvant; live vaccine; pig

Year:  2012        PMID: 32288919      PMCID: PMC7128483          DOI: 10.1016/j.provac.2012.04.018

Source DB:  PubMed          Journal:  Procedia Vaccinol


  15 in total

1.  Investigations towards an efficacious and safe strangles vaccine: submucosal vaccination with a live attenuated Streptococcus equi.

Authors:  A A Jacobs; D Goovaerts; P J Nuijten; R P Theelen; O M Hartford; T J Foster
Journal:  Vet Rec       Date:  2000-11-11       Impact factor: 2.695

Review 2.  Bluetongue vaccines: the past, present and future.

Authors:  V Bhanuprakash; B K Indrani; M Hosamani; V Balamurugan; R K Singh
Journal:  Expert Rev Vaccines       Date:  2009-02       Impact factor: 5.217

Review 3.  Marker vaccine strategies and candidate CSFV marker vaccines.

Authors:  Xiao-Nan Dong; Ying-Hua Chen
Journal:  Vaccine       Date:  2006-08-07       Impact factor: 3.641

Review 4.  Recent advances in immunomodulation and vaccination strategies against coccidiosis.

Authors:  Rami A Dalloul; Hyun S Lillehoj
Journal:  Avian Dis       Date:  2005-03       Impact factor: 1.577

5.  Assessment of the economic impact of porcine reproductive and respiratory syndrome on swine production in the United States.

Authors:  Eric J Neumann; James B Kliebenstein; Colin D Johnson; John W Mabry; Eric J Bush; Ann H Seitzinger; Alice L Green; Jeffrey J Zimmerman
Journal:  J Am Vet Med Assoc       Date:  2005-08-01       Impact factor: 1.936

Review 6.  Age and long-term protective immunity in dogs and cats.

Authors:  R D Schultz; B Thiel; E Mukhtar; P Sharp; L J Larson
Journal:  J Comp Pathol       Date:  2009-12-03       Impact factor: 1.311

7.  Humoral, cell-mediated and mucosal immunity induced by oculo-nasal vaccination of one-day-old SPF and conventional layer chicks with two different live Newcastle disease vaccines.

Authors:  Fabienne Rauw; Yannick Gardin; Vilmos Palya; Steven van Borm; Martine Gonze; Sophie Lemaire; Thierry van den Berg; Bénédicte Lambrecht
Journal:  Vaccine       Date:  2009-04-09       Impact factor: 3.641

8.  Cross-protective immunity to porcine reproductive and respiratory syndrome virus by intranasal delivery of a live virus vaccine with a potent adjuvant.

Authors:  Varun Dwivedi; Cordelia Manickam; Ruthi Patterson; Katie Dodson; Michael Murtaugh; Jordi B Torrelles; Larry S Schlesinger; Gourapura J Renukaradhya
Journal:  Vaccine       Date:  2011-04-03       Impact factor: 3.641

Review 9.  Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus.

Authors:  Dave Cavanagh
Journal:  Avian Pathol       Date:  2003-12       Impact factor: 3.378

10.  Lelystad virus, the causative agent of porcine epidemic abortion and respiratory syndrome (PEARS), is related to LDV and EAV.

Authors:  J J Meulenberg; M M Hulst; E J de Meijer; P L Moonen; A den Besten; E P de Kluyver; G Wensvoort; R J Moormann
Journal:  Virology       Date:  1993-01       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.